{"id":493,"date":"2022-05-31T16:27:37","date_gmt":"2022-05-31T08:27:37","guid":{"rendered":"https:\/\/neurotechinternational.com\/?page_id=493"},"modified":"2022-07-08T08:39:06","modified_gmt":"2022-07-08T00:39:06","slug":"biopharmaceutical-trials","status":"publish","type":"page","link":"https:\/\/neurotechinternational.com\/biopharmaceutical-trials\/","title":{"rendered":"Biopharmaceutical Trials"},"content":{"rendered":"\n
<\/div>
<\/div><\/div>\n
<\/div>\n\n\n\n

Neurotech International is conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI\/Dolce cannabis strains.<\/h1>\n\n\n\n
<\/div>\n<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

Ground-breaking NTI164 treatment to improve quality of life.<\/h2>\n\n\n\n

Neurotech\u2019s leading treatment, NTI164 is providing solutions for the treatment of conditions that improve quality of life. Our current development program is a world-first clinical trial using NTI164 to treat Paediatric Autism Spectrum Disorder (ASD) at Monash Children\u2019s Hospital, Melbourne.<\/p>\n\n\n\n

Phase I\/II trial results demonstrated successful outcomes relating to the safety, tolerability and efficacy of NTI164 on key behavioural parameters with 93% of participants showing symptom improvement.<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

NTI164<\/h2>\n\n\n\n
<\/div>\n\n\n\n